Tech Company Financing Transactions
Cytovation Funding Round
Canica and Sandwater participated in a $8 million Series A venture round for Cytovation. The financing round was announced by the company on 6/2/2023.
Transaction Overview
Company Name
Announced On
6/2/2023
Transaction Type
Venture Equity
Amount
$8,000,000
Round
Series A
Proceeds Purpose
The company intends to use the funds to support the progress of its lead asset, CyPep-1, into a full Phase 2 program for the treatment of solid tumors.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Solheimsgaten 11
Bergen, 5058
NO
Bergen, 5058
NO
Phone
Undisclosed
Website
Email Address
Overview
Cytovation is a clinical stage biotech developing CyPep-1, the first synthetic peptide engineered to selectively target tumor cell membranes based on their altered molecular composition. CyPep-1 lyses the cell membranes, exposes antigenic material from within the cancer cells, and induces a tumor-specific immune response. The described mode of action is effective across cancer types and highly synergistic with checkpoint inhibitors.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Per Lønning
Chief Executive Officer
Lars Prestegarden
Chief Operating Officer
Federico Grego
Co-Founder
Rolf Bjerkvig
Browse more venture capital transactions:
Prev: 6/2/2023: Fortify venture capital transaction
Next: 6/2/2023: Red 6 venture capital transaction
Share this article
About Our Venture Capital Transactions Database
Our team works diligently to report on every notable VC transaction. VC investment data records reported here come from company press releases and news coverage. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs